InvestSMART

Bio-Gene Technology Ltd (ASX:BGT)

ALERT: Price-sensitive ASX Announcement for BGT
Current share price for BGT : $0.017 -0.014 (-45.16%)+
Announcement
Release
24 Feb 2026 9:35AM
Price at Release
$0.031
Full Release
download
Summary
Bio-Gene Technology Ltd, an Australian company specializing in the development of novel bio-insecticides, has reported its half-year financial results for the period ending 31 December 2025. The company experienced a significant revenue increase of 516.4% to A$466,000, while the net loss decreased by 4.4% to A$1,400,687. Bio-Gene has been focusing on its product pipeline, including Flavocide and Qcide, targeting insect resistance and toxicity across various sectors. Qcide, a natural pesticide, was approved by the US Organic Materials Review Institute, facilitating its use in organic production systems. The company also raised A$2.46 million from placements and share purchase plans to support its ongoing development activities. Despite the progress, financial statements indicate material uncertainty regarding the company's ability to continue as a going concern without successful future fundraising.
Key Points
  • Revenues increased by 516.4% to A$466,000.
  • Net loss decreased by 4.4% to A$1,400,687.
  • Qcide approved by the US Organic Materials Review Institute.
  • A$2.46 million raised from placements and share purchase plans.
  • Material uncertainty regarding going concern without future fundraising.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.